Abstract -Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primary outcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], <132; tertile 2 [T2], 132-145; and tertile 3 [T3], >145 mm Hg). Participants with higher baseline SBP tertile were more often women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins, and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer in the T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction (P=0.77). Event rates were lower in the intensive arm, and there was no evidence that this benefit differed by SBP tertile. There was no difference in the hazard for serious adverse events in any of the 3 tertiles. Medication utilization differed across the SBP tertiles at baseline with a lesser percentage of diuretics and angiotensin-converting enzyme inhibitors/ angiotensin receptor blocker drugs in the higher tertiles-a finding that reversed during the trial. The beneficial effects of intensive SBP lowering were not modified by the level of baseline SBP. Within the parameters of this population, these findings add support for clinicians to treat blood pressure to goal irrespective of baseline SBP. (Hypertension.
S ystolic hypertension is a major risk factor for cardiovascular disease (CVD), with strong evidence suggesting that a strategy of intensive blood pressure (BP) control provides favorable outcomes. [1] [2] [3] SPRINT (Systolic Blood Pressure Intervention Trial) compared outcomes of 9361 patients treated to a target systolic BP (SBP) of <120 (intensive treatment) versus <140 mm Hg (standard treatment). 4 SPRINT enrolled patients who were nondiabetic, at least 50 years old, had an SBP of 130 to 180 mm Hg at screening, and were considered to be at increased risk of cardiovascular events. The primary outcome was a composite of nonfatal myocardial infarction, non-myocardial infarction acute coronary syndrome, stroke, acute decompensated heart failure (HF), or death from CVD cause. Intensive SBP treatment reduced the primary outcome by 25% and all-cause mortality by 27%, along with a 38% decrease in HF and a 43% decrease in death from CVD. Data from the National Health and Nutrition Examination Survey suggest that 16.8 million US adults (7.6%) would fulfill the SPRINT eligibility criteria and thus potentially benefit from intensive BP control. 5 Whether the findings of SPRINT may be generalizable to other patient populations is unknown.
5,6

Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)
In SPRINT, the benefits of intensive SBP lowering were found to be consistent across the prespecified subgroups of special interest, including baseline SBP tertiles. 4 The hazard ratios (HRs) favoring intensive versus standard therapy were 0.70 (95% confidence interval [CI] , 0.50-0.95), 0.77 (95% CI, 0.57-1.03), and 0.83 (95% CI, 0.63-1.09), in the lowest (<132 mm Hg, tertile 1 [T1]), middle (132-145 mm Hg, tertile 2 [T2]), and highest (>145 mm Hg, tertile 3 [T3]) tertiles of baseline SBP, respectively, with no heterogeneity of effect among the tertiles (P=0.77).
The purpose of the present report was to expand on the previously reported findings by providing a more detailed analysis of treatment differences and primary outcome component event rates by baseline SBP tertiles. Accordingly, we examined, by tertile, baseline characteristics and risk factors, outcomes, adverse events, differences in utilization of CVD guideline-based medications, and BP at baseline and followup among the SBP tertile groups.
Methods
Study Design and Population
Anonymized data and materials have been made publicly available at the Biolincc and can be accessed at https://biolincc.nhlbi.nih.gov/ studies/sprint_pop/. Adults with SBP 130 to 180 mm Hg who were at least 50 years old and who were considered to be at increased risk of CVD were randomized at 102 clinical sites to intensive (SBP, <120 mm Hg) or standard (SBP, <140 mm Hg) treatment arms as described previously. 4, 7 Any antihypertensive medications were not to be changed by SPRINT during the baseline period. After randomization, participants underwent adjustment of antihypertensive therapy based on accepted treatment algorithms that encouraged adherence to medication classes recognized to have beneficial effects in preventing CVD outcomes. Study visits were conducted monthly for the first 3 months, and then every 3 months. Participants could be seen more frequently for adjustment of their antihypertensive medications based on their level of BP. At each visit, 3 BPs were measured by trained clinical staff using standardized procedures, including proper cuff size, positioning in a chair with back support, and use of an automated BP device (Omron-HEM-907 XL). BPs were measured early in the visit and not following stressful examination components, such as venipuncture. The Manual of Procedures stated that participants should be resting, not completing questionnaires, and not speaking with study staff during the 5-minute rest period before, and while, BP measurements were being taken. The Manual of Procedures also stated that staff should leave the room during the 5-minute rest period and provided a script that staff could use to explain that they would be absent during the 5-minute rest period and would then enter the room and obtain the measurements without speaking to the participant. For most participants in the intensive group, a 2-or 3-drug regimen was established at randomization. Drug doses were increased and additional antihypertensive medications were added at monthly visits until the target of <120 was reached or the investigator decided that no further medications should be added. For standard group participants, the protocol was designed to achieve an SBP of 135 to 139 mm Hg, starting with the randomization visit. Dose titration or addition of another drug occurred if SBP was >160 mm Hg at a single visit or >140 mm Hg at 2 successive visits. Medication might be reduced if the SBP was <130 at a single visit or <135 at 2 consecutive visits. 7 Recruitment was planned to take 2 years with follow-up of ≤6 years. However, the treatment by SPRINT centers was terminated early for benefit after a median follow-up of 3.26 years, and participants were informed of the results. Institutional review board approval for the study was obtained for each clinical site, and all participants provided written informed consent. All procedures on participants were followed in accordance with the institutional guidelines and adhered to the principles of the Declaration of Helsinki and US Code of Federal Regulations.
Study Measurements and Clinical Outcomes
Of those screened, 9361 (64%) were randomized to the intensive or standard treatment arms in a 1:1 design with intention-to-treat analysis specified. Demographic, clinical, and laboratory data were obtained at baseline and every 3 months thereafter as described previously. 4, 7 Potential outcomes were assessed at scheduled quarterly visits, and serious adverse events (SAEs) were assessed at each visit. Outcomes were adjudicated by a committee blinded to treatment group assignment. The primary outcome was a composite of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated HF, or death from cardiovascular cause. Individual components of the primary outcome, along with death from any cause, were secondary outcome measures. One of the prespecified subgroup analyses was by tertile of baseline SBP. Tertiles of baseline SBP were determined after recruitment of the cohort (T1: <132 mm Hg, n=3136; T2: 132-145 mm Hg, n=3038; and T3: >145 mm Hg, n=3187), and results were analyzed by treatment arm (intensive versus standard).
Statistical Analysis
Descriptive summary statistics were produced to compare baseline SBP by tertiles. Means and SDs were calculated for continuous variables, and counts and percentages were calculated for categorical data. Baseline data by tertiles were compared using ANOVA for continuous covariates and χ 2 tests for categorical data. Similar to the primary results analysis, 4 comparison was performed for first occurrence of a primary outcome event between the 2 treatment groups with the use of intention-to-treat approach for all randomly assigned participants. Cox proportional-hazards regression analysis with 2-sided tests at the 0.05 level of significance was used with stratification by clinical site at randomization. Follow-up time was censored on the date of last event ascertainment. Interactions between the treatment and prespecified subgroups were examined using likelihood ratio tests. Cumulative hazard plots by tertile were created to show the treatment effects over time.
Results
Baseline Characteristics
Participants in the T3 group were older (mean age of 68.8±9. 8 [SD] years), more often >75 years of age, included a higher percentage of women (40.8%), were less likely to be on statin or aspirin therapy, or on antihypertensive medications at baseline as compared with T1 and T2 ( 
Differences in BP at Baseline and Follow-Up
Mean SBP in T1 declined from 123.6±7.5 to 118.6±13.5 mm Hg in the intensive arm through year 4, whereas those in the standard arm demonstrated an increase in SBP from 123.8±7.1 to 134.4±14.1 mm Hg (Table 2) . Mean diastolic BP (DBP) in T1 declined from 72.3±9.6 to 67.2±9.1 in the intensive arm through year 4, whereas those in the standard arm demonstrated an increase in DBP from 71.9±9.6 to 76.2±9.7 mm Hg. The mean number of antihypertensive medications increased in the intensive and declined in the standard arm ( Figure 1A ). Mean SBP and DBP declined in both intensive and standard arms in T2 and T3 during the same interval (T2: groups and increased by 3.4 in standard T1, with a decline in standard T2 and T3 of 3.1 and 10.0 mm Hg. Achieved SBP was marginally higher across the tertiles in both treatment arms (intensive T1, T2, and T3: 118.6, 120.8, and 122.2, and standard: 134.4, 135.8, and 139.3; Figure S1 in the onlineonly Data Supplement). Fewer participants in T3 achieved BP targets compared with T1 and T2. BP control (<140/90) was achieved in 92% (T1), 91% (T2), and 88% (T3) of participants in the intensive arm compared with 65% (T1), 62% (T2), and 57% (T3) in the standard arm.
Primary Outcome, Event Rates, and Adverse Effects
Event rates for all clinical outcomes were lower in the intensive compared with the standard treatment arm (Table S1) The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1 (HR, 0.70; CI, 0.51-0.95), 23% in T2 (HR, 0.77; CI, 0.57-1.03), and 17% in T3 (HR, 0.83; CI, 0.63-1.09). There was no evidence that the benefit of intensive treatment differed by SBP tertile (interaction P=0.77). Cumulative hazards plots, by tertile of baseline SBP, for the primary outcome are shown in Figure 2 . There was no evidence of a significant modification of treatment effect by category of the other prespecified SPRINT subgroups of special interest in any of the 3 tertiles (all interaction P values >0.05; Figure 3 ). There was no significant difference in the HR for SAEs (intensive versus standard) in any of the 3 tertiles of baseline SBP (Table 3) . Intensive participants had more hypotension and acute kidney injury, but there was no significant interaction between tertile and treatment for any measured adverse event (all interaction P values >0.16). 
Differences in Medication Utilization
Most participants (90.6%) were using antihypertensive medication at baseline (Table 1) . After randomization, medications were adjusted per protocol resulting in intensive participants being on more antihypertensive medications as compared with those in the standard arm, across the SBP tertiles (Table S2). Throughout follow-up, the number of medications was higher in the intensive participants, whereas medication number remained unchanged in the standard group except for a decline in T1. Medication use was compared based on class, including diuretics, angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor blockers, β-blockers, and calcium channel blockers. Differences in medication utilization across the SBP tertiles at baseline and during the trial were noted, with slightly fewer antihypertensive agents used in the higher tertiles at baseline, including a lower percentage of diuretics and ACE-I/angiotensin receptor blocker drugs-a finding that reversed during the trial. Although the use of all classes of medications was increased compared with baseline in all tertiles among those in the intensive arm, there was a decrease in utilization of all classes in the standard T1, except for calcium channel blockers. There was little or no difference in use of all classes in standard T2 and small increases in utilization of diuretics, ACE-I/angiotensin receptor blocker, and calcium channel blockers in the standard T3.
Discussion
BP has been established as an independent risk factor for CVD and cerebrovascular outcomes, and clinical trial results have consistently demonstrated benefit from lowering BP. 4, [8] [9] [10] [11] [12] The beneficial effects of the SPRINT intervention on the rate of the primary outcome, rate of death from any cause, and development of acute HF on the entire cohort were substantial. The purpose of this study was to examine whether the effects on clinical and adverse outcomes of intensive SBP lowering to target <120 mm Hg versus standard lowering to target <140 mm Hg in SPRINT differed by baseline SBP. We observed similar effects of the intensive treatment outcomes across all 3 baseline SBP tertiles. Intensive treatment resulted in no heterogeneity of effect among baseline SBP tertiles in cardiovascular outcomes or rates of SAEs. This benefit was seen even in the lowest SBP tertile, despite lower baseline DBP levels in this subgroup, as well as follow-up DBP averaging ≈68 mm Hg. Beddhu et al 13 recently reported that although there are U-shaped relationships between baseline DBP and the primary CVD outcome and all-cause death in SPRINT, the beneficial effect of intensive SBP lowering on the primary CVD outcome and all-cause death was not modified by baseline DBP. These findings add important evidence on the consideration of baseline BP in treatment decision-making for patients considered to be at increased risk of cardiovascular events.
Whether such benefits may be modified by baseline SBP has been examined in previous trials with conflicting results. In 2 large systematic review and meta-analysis studies, there was no evidence that benefits varied by baseline SBP. Xie et al 2 examined 19 trials involving 45 000 participants followed for mean 3.8 years and found benefit of intensive BP lowering with risk reduction for cardiovascular events and death that was consistent across baseline SBP tertiles. Similarly, Ettehad et al 3 reported risk reductions across lower to higher baseline SBP levels in an analysis of 123 studies and 614 000 participants. On the other hand, the HOPE (Heart Outcomes Prevention Evaluation)-3 BP trial investigators reported that the apparent benefits of BP lowering were limited to the highest SBP tertile (>143.5 mm Hg).
14 There are important differences between SPRINT and the HOPE-3 BP trial.
14,15 The HOPE-3 BP trial examined the effect of a fixed-dose combination antihypertensive drug (low-dose hydrochlorothiazide plus candesartan) but not a specific BP target in prevention of CVD events. Compared with SPRINT, the HOPE-3 BP trial enrolled a population with much lower average CVD risk and achieved a much smaller difference in SBP between the 2 treatment groups (13 mm Hg in SPRINT versus 6 mm Hg in HOPE-3). Although overall there was no significant benefit of the antihypertensive treatment in reducing cardiovascular events in the HOPE-3 BP trial, the effect of the BP intervention on outcomes suggested a 24% to 27% lower risk of primary outcomes, including cardiovascular events and death in the highest SBP tertile.
14 In contrast to the HOPE-3 BP trial, the SPRINT results suggest that participants in each tertile of baseline SBP derived similar benefit from intensive BP control. Possible explanations for the differences in results by tertile of baseline BP in the 2 trials have been reviewed extensively and include choice of a low-risk population and use of lower doses of the antihypertensive medication, as well as attainment of a smaller difference in achieved SBP levels in the HOPE-3 BP trial. 15, 16 We examined treatment differences and primary outcome component event rates by baseline SBP tertiles, including, by tertile, baseline characteristics and risk factors, outcomes, adverse events, differences in utilization of CVD guidelinebased medications, and BP at baseline and follow-up. We found differences in baseline characteristics among the baseline SBP tertiles, which were determined after recruitment of the cohort (T1: <132 mm Hg, n=3136; T2: 132-145 mm Hg, n=3038; and T3: >145 mm Hg, n=3187). Participants with higher baseline BP were more often women and tended to be older, have a higher CVD risk, and have a lower utilization of antihypertensive medications, statins, and aspirin. Differences in achieved BP targets were apparent across the SBP tertiles and the 2 treatment arms; achieved BP in both treatment arms was slightly higher in T2 and T3 compared with T1, and fewer in the T3 groups achieved targets compared with T1 and T2 groups. Comparing baseline to follow-up SBP through year 4, there were declines of 6, 18, and 33 mm Hg across intensive T1, T2 and T3: an increase in standard T1 of 11 mm and a decline in standard T2 and T3 of 3 mm and 16 mm Hg, with a similar pattern and smaller DBP changes. The rise in BP during the trial in T1 standard group is likely a combination of reduction in medication and regression toward the mean. Medication adjustment was detailed in the SPRINT protocol in the standard arm to achieve an SBP level between 135 and 139 mm Hg. Down titration was specified if the SBP was <130 mm Hg at a single visit or <135 mm Hg at 2 consecutive visits. 17 Event rates were lower in the intensive compared with standard treatment arms, and there was no evidence that this benefit differed by SBP tertile. There was no difference in the hazard for serious adverse effects overall or in any of the 3 tertiles of baseline SBP. Overall, intensive participants had more electrolyte disorders, hypotension, acute kidney injury, and syncope, and this pattern was similar in the 3 SBP tertiles. There was no evidence of modification of treatment effect by SBP tertile of age, sex, race, chronic kidney disease, or prior CVD. Entering baseline visit, all but 9% of participants were using antihypertensive medication. Differences in medication utilization across the SBP tertiles at baseline and during the trial were noted, with slightly less antihypertensive agents used in the higher tertiles at baseline, including a smaller percentage of diuretics and ACE-I/angiotensin receptor blocker drugs-a finding that reversed during the trial. Taken together, these findings confirm and extend the previously reported interaction test of baseline SBP tertiles by treatment arm that revealed no heterogeneity of effect in SPRINT. 4 The primary results of SPRINT were consistent across the baseline SBP tertiles, and this study provides additional evidence in support of intensive BP lowering, irrespective of starting BP, albeit with careful attention to potential adverse events.
Limitations of SPRINT are noteworthy. SPRINT did not include individuals with prior history of stroke, those with known diabetes mellitus, polycystic kidney disease, symptomatic HF, proteinuria >1 g/d, chronic kidney disease <20 mL/min per 1.73 m2, or those with dementia or residing in nursing homes; therefore, these results are not necessarily generalizable to these populations. Investigators and participants in SPRINT were not blinded to treatment assignments. This was a secondary analysis, and although the subgroups were prespecified in SPRINT, the study was not designed or powered to formally test treatment differences in the subgroups, including SBP tertiles. Taken together with the fact that SPRINT was stopped early for benefit, it is not surprising that there was no significant treatment effect in 2 of the 3 tertiles. However, the point estimates for all 3 were in the same direction, and there was no evidence of heterogeneity of effect. Whether the observed spread in these point estimates has any meaning would be speculative, but the following factors may have influenced the point estimates: differences in baseline characteristics, the reduction in total medications in standard T1 compared with an increase in intensive T1, higher achieved BP, or fewer guideline-based medications in the higher tertiles. HF was one of the most frequent outcomes in SPRINT, and although higher baseline BP was associated with an independent predictor of acute decompensated HF risk, the benefit of intensive treatment on this event rate was consistent across the prespecified subgroups, including the baseline SBP tertiles. 18 Differences in baseline characteristics among the tertiles suggested higher risk in the higher tertiles, including more untreated hypertension and less statin and aspirin use at baseline. Of note, higher absolute risk is expected to enhance treatment benefit. 19 Although primary outcome data were obtained with the same frequency in both treatment arms, adverse events were self-reported at each visit, and, given that the intensive group had more visits for BP management, ascertainment bias may have affected SAE results, which should be, therefore, interpreted with caution.
Perspectives
In this unadjusted analysis, the impact of intensive treatment on clinical and SAEs did not differ by tertiles of baseline SBP in SPRINT. SBP lowering seems to benefit across the spectrum of baseline SBP, even among those in the lowest tertile of SBP at baseline and even in the face of low levels of DBP. These findings may be helpful to clinicians when considering level of baseline SBP in decision-making on intensive BP lowering for individual patients, at least in those deemed to be at an increased risk of CVD and without stroke or diabetes mellitus.
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